Global Fludeoxyglucose (18F) Radionuclide Injection Market Size By Type (Cancer, Coronary Artery Disease), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Fludeoxyglucose (18F) Radionuclide Injection Market Report Description

The Global Fludeoxyglucose (18F) Radionuclide Injection Market was valued at USD 460 million in 2023 and is projected to reach USD 785 million by 2031, growing at a CAGR of 6.8% during the forecast period (2023–2031). Fludeoxyglucose (18F) is a key radiopharmaceutical used in positron emission tomography (PET) imaging, widely employed in oncology, neurology, and cardiology diagnostics. The market is driven by rising cancer prevalence, increased adoption of PET/CT imaging, and advancements in radiopharmaceutical production and distribution logistics.

Drivers:

Rising Cancer Incidence and Diagnostic Imaging Demand:

The increasing global burden of cancer has significantly boosted the demand for advanced imaging modalities. FDG (18F) is crucial in detecting metabolic activity and staging cancer, thereby becoming an indispensable diagnostic tool.

Expansion of PET/CT Imaging Centers:

Healthcare infrastructure development, particularly in emerging economies, is leading to the proliferation of PET/CT imaging centers. This expansion fuels the consistent demand for FDG (18F) injections.

Government Support for Nuclear Medicine:

Various governments are supporting nuclear medicine through funding and regulatory frameworks, improving accessibility and standardization in FDG production and application.

Restraints:

Short Half-Life and Supply Chain Challenges:

FDG (18F) has a short half-life of approximately 110 minutes, requiring efficient and time-sensitive radiopharmaceutical logistics. This limits usage in regions lacking PET cyclotron facilities or quick delivery networks.

High Operational Costs:

Production and storage of radionuclide injections require specialized infrastructure and personnel, making the process capital-intensive. These costs may deter new market entrants and affect affordability.

Opportunity:

Technological Innovations in Radiopharmaceuticals:

Advancements in automated synthesis modules, microfluidic radiochemistry, and hybrid imaging platforms provide opportunities for improving FDG production efficiency and expanding clinical applications.

Emerging Markets and Diagnostic Awareness:

Increasing healthcare awareness, infrastructure investment, and government programs in Asia-Pacific and Latin America are fostering untapped opportunities for market expansion.

Market by System Type Insights:

The market is segmented into On-site Cyclotron Production Systems and Off-site Supply Chain Models. In 2023, the Off-site Supply Chain Model held the largest share, benefiting from regional distribution hubs operated by specialized radiopharmaceutical providers. However, On-site Cyclotron Production Systems are expected to grow rapidly due to increasing investments by hospitals and imaging centers to reduce dependency on third-party suppliers and ensure timely access.

Market by End-use Insights:

Based on end-use, Oncology Centers dominated the market in 2023, accounting for more than 60% of global revenue. The dominance is driven by the high utilization of FDG (18F) PET imaging in cancer diagnosis and treatment planning. Neurology Clinics are also experiencing rising adoption due to growing incidences of neurodegenerative disorders like Alzheimer’s disease, where FDG imaging helps assess cerebral metabolism.

Market by Regional Insights:

In 2023, North America held the largest market share due to its established nuclear medicine infrastructure, presence of key players, and high healthcare expenditure. Europe followed closely, with active radiopharmaceutical research hubs. Asia-Pacific is expected to witness the highest growth through 2031, propelled by increasing investments in healthcare infrastructure, government nuclear medicine initiatives, and growing patient populations.

Competitive Scenario:

Key players in the Global Fludeoxyglucose (18F) Radionuclide Injection Market include Siemens Healthineers, Cardinal Health, GE Healthcare, Curium Pharma, SOFIE Biosciences, Advanced Accelerator Applications (Novartis), Jubilant Radiopharma, and Lantheus Holdings, Inc. These companies are focusing on capacity expansion, strategic collaborations, and technological upgrades to enhance radiopharmaceutical supply chains.

Scope of Work – Global Fludeoxyglucose (18F) Radionuclide Injection Market

Report Metric Details

Market Size (2023) USD 460 million

Projected Market Size (2031) USD 785 million

CAGR (2023–2031) 6.8%

Market Segments By System Type (On-site, Off-site), End-use, Region

Growth Drivers Rising cancer prevalence, PET/CT center expansion, government support

Opportunities Emerging markets, production innovations

Key Market Developments:

May 2023: GE Healthcare expanded its PET radiopharmacy network in North America to increase same-day delivery capabilities for FDG (18F) and other PET tracers.

August 2023: Siemens Healthineers partnered with leading oncology hospitals in Europe to co-develop next-gen automated FDG production modules.

January 2024: Curium Pharma announced the establishment of a new cyclotron facility in India aimed at strengthening its footprint in the Asia-Pacific PET diagnostics market.

FAQs:

What is the current market size of the Global Fludeoxyglucose (18F) Radionuclide Injection Market?

The market was valued at USD 460 million in 2023.

What is the major growth driver of the Global Fludeoxyglucose (18F) Radionuclide Injection Market?

Rising prevalence of cancer and the growing adoption of PET/CT imaging are the key growth drivers.

Which is the largest region during the forecast period in the Global Fludeoxyglucose (18F) Radionuclide Injection Market?

North America leads the market due to its mature radiopharmaceutical supply network and healthcare infrastructure.

Which segment accounted for the largest market share in Global Fludeoxyglucose (18F) Radionuclide Injection Market?

The Oncology Centers segment held the largest market share in 2023.

Who are the key market players in the Global Fludeoxyglucose (18F) Radionuclide Injection Market?

Major players include Siemens Healthineers, Cardinal Health, GE Healthcare, Curium Pharma, and SOFIE Biosciences.

Let me know if you’d like this report exported into a document or customized for presentation use.